{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:29:36Z","timestamp":1791268176036,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,5,7]],"date-time":"2015-05-07T00:00:00Z","timestamp":1430956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Bone Oncology"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1016\/j.jbo.2015.06.002","type":"journal-article","created":{"date-parts":[[2015,7,29]],"date-time":"2015-07-29T16:25:01Z","timestamp":1438187101000},"page":"59-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["RANK and RANK ligand expression in primary human osteosarcoma"],"prefix":"10.1016","volume":"4","author":[{"given":"Daniel","family":"Branstetter","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Rohrbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ya","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosalia","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Tometsko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Blake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison P.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Dougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jbo.2015.06.002_bib1","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1309\/UC6KQHLD9LV2KENN","article-title":"Osteosarcoma: anatomic and histologic variants","volume":"125","author":"Klein","year":"2006","journal-title":"Am J Clin Pathol"},{"key":"10.1016\/j.jbo.2015.06.002_bib2","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.bone.2014.02.003","article-title":"Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells?","volume":"62","author":"Mutsaers","year":"2014","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2015.06.002_bib3","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.coph.2014.02.002","article-title":"Recent advances in osteosarcoma","volume":"16","author":"Botter","year":"2014","journal-title":"Curr Opin Pharmacol"},{"key":"10.1016\/j.jbo.2015.06.002_bib4","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrd3705","article-title":"Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab","volume":"11","author":"Lacey","year":"2012","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jbo.2015.06.002_bib5","doi-asserted-by":"crossref","first-page":"5132","DOI":"10.1200\/JCO.2010.29.7101","article-title":"Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study","volume":"28","author":"Stopeck","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbo.2015.06.002_bib6","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1200\/JCO.2010.31.3304","article-title":"Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma","volume":"29","author":"Henry","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbo.2015.06.002_bib7","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2015.06.002_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.jbo.2015.06.002_bib9","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jbo.2015.06.002_bib10","first-page":"1231","article-title":"Increased osteoclast activity is associated with aggressiveness of osteosarcoma","volume":"33","author":"Avnet","year":"2008","journal-title":"Int J Oncol"},{"key":"10.1016\/j.jbo.2015.06.002_bib11","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1359\/jbmr.2000.15.9.1766","article-title":"Importance of membrane- or matrix-associated forms of M-CSF and RANKL\/ODF in osteoclastogenesis supported by SaOS-4\/3 cells expressing recombinant PTH\/PTHrP receptors","volume":"15","author":"Itoh","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jbo.2015.06.002_bib12","first-page":"133","article-title":"Expression of receptor activator of nuclear factor kappa-B ligand (RANKL) in neoplasms of dogs and cats","volume":"21","author":"Barger","year":"2007","journal-title":"J Vet Intern Med"},{"key":"10.1016\/j.jbo.2015.06.002_bib13","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/pbc.22720","article-title":"RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma","volume":"56","author":"Lee","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.jbo.2015.06.002_bib14","doi-asserted-by":"crossref","first-page":"7308","DOI":"10.1158\/0008-5472.CAN-06-4130","article-title":"Therapeutic relevance of osteoprotegerin gene therapy in osteosarcoma: blockade of the vicious cycle between tumor cell proliferation and bone resorption","volume":"67","author":"Lamoureux","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.jbo.2015.06.002_bib15","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1172\/JCI42391","article-title":"Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice","volume":"120","author":"Molyneux","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jbo.2015.06.002_bib16","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1211\/jpp.62.04.0009","article-title":"Systemic RANK-Fc protein therapy is efficacious against primary osteosarcoma growth in a murine model via activity against osteoclasts","volume":"62","author":"Akiyama","year":"2010","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.jbo.2015.06.002_bib17","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10585-010-9319-y","article-title":"RANK-Fc inhibits malignancy via inhibiting ERK activation and evoking caspase-3-mediated anoikis in human osteosarcoma cells","volume":"27","author":"Akiyama","year":"2010","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.jbo.2015.06.002_bib18","doi-asserted-by":"crossref","first-page":"3389","DOI":"10.1158\/1535-7163.MCT-08-0497","article-title":"Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma","volume":"7","author":"Lamoureux","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.jbo.2015.06.002_bib19","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bone.2005.02.020","article-title":"Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma","volume":"37","author":"Heymann","year":"2005","journal-title":"Bone"},{"key":"10.1016\/j.jbo.2015.06.002_bib20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1002\/path.2140","article-title":"Human osteosarcoma cells express functional receptor activator of nuclear factor-kappa B","volume":"211","author":"Mori","year":"2007","journal-title":"J Pathol"},{"key":"10.1016\/j.jbo.2015.06.002_bib21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1242\/jcs.094029","article-title":"Homotypic RANK signaling differentially regulates proliferation, motility and cell survival in osteosarcoma and mammary epithelial cells","volume":"125","author":"Beristain","year":"2012","journal-title":"J Cell Sci"},{"key":"10.1016\/j.jbo.2015.06.002_bib22","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/PAT.0000000000000116","article-title":"Impact of RANK signalling on survival and chemotherapy response in osteosarcoma","volume":"46","author":"Bago-Horvath","year":"2014","journal-title":"Pathology"},{"key":"10.1016\/j.jbo.2015.06.002_bib23","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1158\/1078-0432.CCR-12-0578","article-title":"Denosumab induces tumor reduction and bone formation in patients with giant-cell tumor of bone","volume":"18","author":"Branstetter","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jbo.2015.06.002_bib24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1470-2045(10)70010-3","article-title":"Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study","volume":"11","author":"Thomas","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jbo.2015.06.002_bib25","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(13)70277-8","article-title":"Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study","volume":"14","author":"Chawla","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jbo.2015.06.002_bib26","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s10585-013-9624-3","article-title":"RANK expression on breast cancer cells promotes skeletal metastasis","volume":"31","author":"Blake","year":"2014","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.jbo.2015.06.002_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0022-1759(99)00087-3","article-title":"Standardisation of a procedure for quantifying surface antigens by indirect immunofluorescence","volume":"228","author":"Smith","year":"1999","journal-title":"J Immunol Methods"},{"key":"10.1016\/j.jbo.2015.06.002_bib28","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jbo.2015.06.002_bib29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/36593","article-title":"A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function","volume":"390","author":"Anderson","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.jbo.2015.06.002_bib30","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nlm.2013.09.001","article-title":"Hippocampal alpha7-nicotinic cholinergic receptors modulate memory reconsolidation: a potential strategy for recovery from amnesia","volume":"106","author":"Blake","year":"2013","journal-title":"Neurobiol Learn Mem"},{"key":"10.1016\/j.jbo.2015.06.002_bib31","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1002\/pros.20678","article-title":"RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes","volume":"68","author":"Armstrong","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.jbo.2015.06.002_bib32","doi-asserted-by":"crossref","first-page":"R112","DOI":"10.1186\/bcr3234","article-title":"Identification of novel human receptor activator of nuclear factor-kB isoforms generated through alternative splicing: implications in breast cancer cell survival and migration","volume":"14","author":"Papanastasiou","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.jbo.2015.06.002_bib33","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/bonekey.2014.14","article-title":"Targeting RANKL in metastasis","volume":"3","author":"Dougall","year":"2014","journal-title":"Bonekey Rep"},{"issue":"5","key":"10.1016\/j.jbo.2015.06.002_bib34","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1002\/pbc.22720","article-title":"RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma","volume":"56","author":"Lee","year":"2011","journal-title":"Pediatr Blood Cancer."},{"issue":"9","key":"10.1016\/j.jbo.2015.06.002_bib35","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1172\/JCI42391","article-title":"Prkar1a is an osteosarcoma tumor suppressor that defines a molecular subclass in mice","volume":"120","author":"Molyneux","year":"2010","journal-title":"J Clin Invest."}],"container-title":["Journal of Bone Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137415300063?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212137415300063?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:16:09Z","timestamp":1761941769000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212137415300063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,9]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["S2212137415300063"],"URL":"https:\/\/doi.org\/10.1016\/j.jbo.2015.06.002","relation":{},"ISSN":["2212-1374"],"issn-type":[{"value":"2212-1374","type":"print"}],"subject":[],"published":{"date-parts":[[2015,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"RANK and RANK ligand expression in primary human osteosarcoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Bone Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbo.2015.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier GmbH","name":"copyright","label":"Copyright"}]}}